Flexion Therapeutics Named One of Boston Business Journal’s Best Places to Work
June 23 2017 - 9:00AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it
has been recognized as one of the The Boston Business Journal’s
“Best Places to Work.” Flexion ranked 5th in the medium business
category (100 to 249 employees) and was presented with the award at
a ceremony held last night at Symphony Hall in Boston.
The Best Places to Work program honors leading employers from
the greater Boston area for going “above and beyond” to create an
exceptional work environment for their employees. Companies must
have a physical office in Massachusetts and are judged based on the
results of an employee survey evaluating: communication and
resources, individual needs, manager effectiveness, personal
engagement, team dynamics and trust in leadership.
Flexion’s mission is to advance transformative therapies that
have the potential to make a meaningful difference for patients
confronting musculoskeletal conditions. The company is
distinguished by five core values that define its culture – focus,
ingenuity, tenacity, transparency and fun. These values serve as
the pillars upon which co-founders, Michael Clayman, M.D.,
President and Chief Executive Officer and Neil Bodick, M.D., Ph.D.,
Chief Scientific Officer, established and grew Flexion. In 2016,
the company expanded from 50 to 100 employees, and it plans to
reach approximately 250 people by the end of 2017.
“We have a remarkably talented team of people with deep
expertise and unrivaled passion,” said Dr. Clayman. “From the
outset, Neil and I appreciated the importance of attracting
outstanding professionals who truly share our vision and want to be
a part of a high-performing, respectful and collaborative
organization. We have worked hard to create and foster a culture
that values great ideas and gives everyone a voice. We are honored
by this recognition and extend our sincere gratitude to our
colleagues who live and breathe our core values and make Flexion
such a fun place to work.” About Flexion
Therapeutics Flexion is a specialty pharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis (OA). The company's lead
product candidate, Zilretta™ (FX006), is being investigated for its
potential to provide improved analgesia for the millions of U.S.
patients who receive intra-articular injections for OA related knee
pain annually.
Corporate Contact:
Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2024 to May 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From May 2023 to May 2024